Are dysfunctional relations between academia and industry hindering the process of turning progress
in our understanding of cancer into truly effective treatments? We asked Lex Eggermont, director of
the Gustave Roussy Cancer Institute and Bill Hait, global head, Janssen Research & Development

What do you think?

- Is the current drug development model broken?
- Can the drug development business model that gave us imatinib (Glivec) and trastuzumab (Herceptin) deliver effective treatments for more complex tumours?
- Will making sense of more complex tumours require putting much more data into the public domain – and can this be done without jeopardising the commercial sustainability of pharmaceutical companies?

You can read the article here. Press the comment button at the end and share your views.